Search Bar & Filters
Found 4 Actively Recruiting clinical trials
Actively Recruiting
This research evaluates the effects of cryotherapy wraps combined with compression therapy cryocompression compared to cryotherapy wraps alone on the occurrence and severity of chemotherapy-induced peripheral neuropathy in patients with gynecologic cancer. The study is designed to determine if cryotherapy alone is not worse than cryocompression in preventing neuropathy, while also assessing patient tolerability and satisfaction for both treatments. Participants will be randomly assigned to receive either cryotherapy wraps plus compression or cryotherapy wraps alone on both hands and feet during their taxane chemotherapy infusions. These interventions are applied throughout the duration of the chemotherapy cycles, which occur every three weeks for at least six cycles. Alongside treatment, both patients and staff will complete surveys to assess neuropathy symptoms, treatment acceptability, tolerability, and staff satisfaction. During the study, participants will complete the Functional Assessment of Cancer Therapy FACT-NTX and Patient Neurotoxicity Questionnaire PNQ at each infusion visit to monitor neuropathy symptoms. Additional surveys will measure treatment acceptability and tolerability from both patients and healthcare staff. Researchers will monitor for adverse events like frostbite, unexpected hospitalizations, and death. The primary outcome is the change in patient-reported neuropathy symptoms up to two months after chemotherapy, with overall participation lasting about six months.
Actively Recruiting
Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.
Actively Recruiting
Researchers are evaluating radiation therapy with or without the chemotherapy drug cisplatin in patients with stage III-IVA squamous cell carcinoma of the head and neck who have had surgery to remove their tumor. This phase II trial aims to understand if adding cisplatin to radiation therapy improves disease-free survival, especially in relation to different types of p53 gene mutations, which might affect treatment outcomes. The study also looks at side effects and explores genetic changes that could influence new treatments. Participants are randomly assigned to one of two groups one group receives intensity-modulated radiation therapy IMRT alone once daily, five days a week for six weeks, while the other group receives the same radiation schedule combined with weekly intravenous cisplatin over 1 to 2 hours for six weeks. After completing treatment without disease progression or unacceptable side effects, patients enter a follow-up period lasting up to 10 years. During the study, participants undergo assessments including surgical tumor tissue analysis for p53 mutations, imaging tests to exclude distant disease, and regular health evaluations. After treatment, patients are monitored every six months for three years and then annually for seven more years to track disease recurrence or new tumors. The main outcome measured is disease-free survival, focusing on the time from randomization to recurrence, second primary tumor, or death.
Actively Recruiting
This research evaluates patients with metastatic HER-2-positive breast cancer who are at risk of heart damage from trastuzumab-based treatments. It includes two groups one observational group of patients taking beta blockers, ACE inhibitors, or ARBs alongside their cancer therapy, and a smaller randomized group studying whether carvedilol may prevent heart side effects from chemotherapy. The study aims to understand how often heart problems occur and identify factors that predict these risks. Participants are assigned to one of three groups those taking carvedilol twice daily, those receiving no additional treatment, and those already on beta blockers, ARBs, or ACE inhibitors who are observed without intervention. Treatments or observation continue for up to 108 weeks, with repeated cycles every 12 weeks unless disease progresses or side effects occur. The study also collects blood samples and performs heart function imaging to explore biomarkers and measure heart strain. During the study, participants undergo regular echocardiograms every 12 weeks to assess heart function and strain. Researchers monitor for cardiac events, interruptions in cancer therapy, and adherence to medication. Blood samples are taken to bank for future studies. The main outcome is time until the first sign of cardiac dysfunction over about two years. Safety and side effects of treatments are also tracked, and participants are followed until the study ends in 2031.